[HTML][HTML] A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study
P Castelo-Branco, R Leão, T Lipman, B Campbell… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Oncotarget, 2016•ncbi.nlm.nih.gov
The identification of new biomarkers to differentiate between indolent and aggressive
prostate tumors is an important unmet need. We examined the role of THOR (TERT
Hypermethylated Oncological Region) as a diagnostic and prognostic biomarker in prostate
cancer (PCa).
prostate tumors is an important unmet need. We examined the role of THOR (TERT
Hypermethylated Oncological Region) as a diagnostic and prognostic biomarker in prostate
cancer (PCa).
Abstract
The identification of new biomarkers to differentiate between indolent and aggressive prostate tumors is an important unmet need. We examined the role of THOR (TERT Hypermethylated Oncological Region) as a diagnostic and prognostic biomarker in prostate cancer (PCa).
ncbi.nlm.nih.gov